US Bancorp DE Cuts Stock Position in Natera, Inc. $NTRA

US Bancorp DE lowered its stake in Natera, Inc. (NASDAQ:NTRA) by 9.7% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,676 shares of the medical research company’s stock after selling 822 shares during the period. US Bancorp DE’s holdings in Natera were worth $1,297,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Vontobel Holding Ltd. grew its stake in shares of Natera by 58.3% in the 2nd quarter. Vontobel Holding Ltd. now owns 2,917 shares of the medical research company’s stock worth $493,000 after buying an additional 1,074 shares during the last quarter. Maryland State Retirement & Pension System grew its stake in shares of Natera by 17.9% in the 2nd quarter. Maryland State Retirement & Pension System now owns 6,311 shares of the medical research company’s stock worth $1,066,000 after buying an additional 959 shares during the last quarter. Narwhal Capital Management lifted its position in Natera by 33.3% in the 2nd quarter. Narwhal Capital Management now owns 13,325 shares of the medical research company’s stock valued at $2,251,000 after acquiring an additional 3,332 shares in the last quarter. KLP Kapitalforvaltning AS lifted its position in Natera by 1.8% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 44,400 shares of the medical research company’s stock valued at $7,501,000 after acquiring an additional 800 shares in the last quarter. Finally, Chung Wu Investment Group LLC bought a new position in Natera in the 2nd quarter valued at approximately $169,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Price Performance

NASDAQ NTRA opened at $180.54 on Friday. The business’s fifty day moving average price is $167.60 and its 200-day moving average price is $158.07. The stock has a market capitalization of $24.78 billion, a price-to-earnings ratio of -94.52 and a beta of 1.74. Natera, Inc. has a 1-year low of $117.27 and a 1-year high of $187.34.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to analysts’ expectations of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company’s revenue for the quarter was up 32.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

NTRA has been the topic of several analyst reports. Cowen reaffirmed a “buy” rating on shares of Natera in a research report on Friday, August 8th. Barclays reaffirmed an “overweight” rating and issued a $210.00 price objective (up from $190.00) on shares of Natera in a research report on Friday, August 8th. Royal Bank Of Canada set a $268.00 price objective on Natera and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Wednesday, October 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $220.00 price objective (up from $210.00) on shares of Natera in a research report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $196.81.

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $159.99, for a total value of $479,970.00. Following the completion of the sale, the insider directly owned 117,559 shares in the company, valued at $18,808,264.41. This represents a 2.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Steven Leonard Chapman sold 14,083 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $160.00, for a total value of $2,253,280.00. Following the completion of the sale, the chief executive officer owned 154,072 shares of the company’s stock, valued at $24,651,520. This trade represents a 8.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 72,464 shares of company stock worth $10,963,125 over the last three months. 5.63% of the stock is currently owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.